Sugi Predict

Sugi Predict / Compounds / SCHEMBL4840232

SCHEMBL4840232

SCHEMBL4840232

CCOc1nc2[nH]cc(C(=O)C(N)=O)c2cc1C(=O)N1C[C@H](C)N(Cc2ccc(F)cc2)C[C@H]1C

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 8/20 0.45
▸ MAPK11 Q15759 2/20 0.45
▸ MAPK13 O15264 1/20 0.45
▸ MAPK12 P53778 1/20 0.45
▸ NQO2 P16083 1/20 0.45
▸ MAPKAPK2 P49137 1/20 0.45
▸ ACTR2 P61160 1/20 0.45
▸ CCR1 P32246 9/20 0.43
▸ PDK1 Q15118 1/20 0.35
▸ PDK2 Q15119 1/20 0.35
▸ PDK3 Q15120 1/20 0.35
▸ PDK4 Q16654 1/20 0.35
▸ GRM2 Q14416 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4836359 0.92 MAPK14 (0.53) MAPK14MAPK11MAPK13MAPK12NQO2
SCHEMBL4834276 0.92 MAPK14 (0.44) MAPK14MAPK11MAPK13MAPK12NQO2
SCHEMBL6495478 0.91 MAPK14 (0.44) MAPK14MAPK11MAPK13MAPK12NQO2
SCHEMBL6495727 0.89 MAPK14 (0.43) MAPK14MAPK11MAPK13MAPK12NQO2
SCHEMBL6494151 0.89 MAPK14 (0.46) MAPK14MAPK11MAPK13MAPK12NQO2
SCHEMBL6493985 0.88 MAPK14 (0.47) MAPK14MAPK11MAPK13MAPK12NQO2
SCHEMBL4830514 0.83 MAPK14 (0.52) MAPK14MAPK11MAPK13MAPK12NQO2
SCHEMBL4877440 0.83 MAPK14 (0.66) MAPK14MAPK11MAPK13MAPK12NQO2
SCHEMBL5820849 0.83 MAPK14 (0.51) MAPK14MAPK11MAPK13MAPK12NQO2
SCHEMBL4830562 0.82 MAPK14 (0.57) MAPK14MAPK11MAPK13MAPK12NQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7393851-B2 Azaindole derivatives as inhibitors of p38 kinase SCIOS, INC. (US) 2008-07-01 — — US disclosed
US-7393851-B2 Azaindole derivatives as inhibitors of p38 kinase SCIOS, INC. (US) 2008-07-01 — — US disclosed
US-7393851-B2 Azaindole derivatives as inhibitors of p38 kinase SCIOS, INC. (US) 2008-07-01 — — US disclosed
US-7244441-B2 Stents and intra-luminal prostheses containing map kinase inhibitors SCIOS, INC. (US) 2007-07-17 — — US disclosed
US-7244441-B2 Stents and intra-luminal prostheses containing map kinase inhibitors SCIOS, INC. (US) 2007-07-17 — — US disclosed
US-20050288299-A1 Azaindole derivatives as inhibitors of p38 kinase SCIOS INC. 2005-12-29 — — US disclosed
US-20040176598-A1 Azaindole derivatives as inhibitors of p38 kinase SCIOS, INC. 2004-09-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288299-A1 Azaindole derivatives as inhibitors of p38 kinase MAPKAPK2, MAPK1, MAPK3 MAPK14 21/4885MAPK11 44/4885MAPK13 19/4885
US-20040176598-A1 Azaindole derivatives as inhibitors of p38 kinase MAPKAPK2, MAPK1, MAPK4 MAPK14 11/4885MAPK11 44/4885MAPK13 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.